{"title":"探讨特征相关FAM基因及FAM50A表达与肝细胞癌发病及预后的关系。","authors":"Shaohan Wu, Sijun Chen, Xiaofang Sun, Xujian Chen","doi":"10.21037/tcr-2025-171","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) ranks among the deadliest malignancies worldwide, with limited therapeutic options and poor prognosis for advanced-stage patients. The family with sequence similarity (FAM) genes are expected to be potential regulators in tumorigenesis, but their roles in HCC remain poorly understood. This study aimed to systematically investigate the expression profiles and functional roles of FAM genes in HCC.</p><p><strong>Methods: </strong>We leveraged multiple databases, including The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), International Cancer Genome Consortium (ICGC), Gene Expression Omnibus (GEO), Human Protein Atlas (HPA), and Clinical Proteomic Tumor Analysis Consortium (CPTAC), to assess the expression patterns, prognostic implications, DNA methylation, genomic alterations, and associated tumor immune microenvironments of FAM genes. Differentially expressed genes were pinpointed using the DESeq2 package. Least absolute shrinkage and selection operator (LASSO) Cox regression and a nomogram model were employed to identify prognostic FAM genes and estimate the survival outcomes for HCC patients. We performed tissue microarrays and immunohistochemistry on samples from 48 HCC patients to evaluate <i>FAM50A</i> expression. <i>FAM50A</i> was also knocked down in HCC cell lines to investigate its biological functions.</p><p><strong>Results: </strong>Five overexpressed and signature-related FAM genes (<i>FAM50A</i>, <i>FAM83D</i>, <i>FAM104B</i>, <i>FAM220A</i>, and <i>FAM222B</i>) were identified and validated at both mRNA and protein levels. Elevated FAM50A expression was linked to advanced tumor stage, higher grade, and unfavorable prognosis. The constructed prognostic nomogram accurately predicted 1- and 3-year survival outcomes based on tumor stage, status, and <i>FAM50A</i> expression levels. Pathways enriched in <i>FAM50A</i> co-expressed genes included RNA processing, oxidative phosphorylation, and cell cycle regulation. Additionally, <i>FAM50A</i> expression was associated with immune cell infiltration and immune checkpoint activity. Knockdown of <i>FAM50A</i> led to the suppression of HCC cell proliferation, migration, and invasion.</p><p><strong>Conclusions: </strong>This study identifies five FAM genes with prognostic relevance in HCC, among which FAM50A emerges as a potential independent prognostic biomarker and therapeutic target.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 8","pages":"4720-4747"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432667/pdf/","citationCount":"0","resultStr":"{\"title\":\"Exploration of signature-related FAM genes and correlation between FAM50A expression and the pathogenesis and prognosis of hepatocellular carcinoma.\",\"authors\":\"Shaohan Wu, Sijun Chen, Xiaofang Sun, Xujian Chen\",\"doi\":\"10.21037/tcr-2025-171\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) ranks among the deadliest malignancies worldwide, with limited therapeutic options and poor prognosis for advanced-stage patients. The family with sequence similarity (FAM) genes are expected to be potential regulators in tumorigenesis, but their roles in HCC remain poorly understood. This study aimed to systematically investigate the expression profiles and functional roles of FAM genes in HCC.</p><p><strong>Methods: </strong>We leveraged multiple databases, including The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), International Cancer Genome Consortium (ICGC), Gene Expression Omnibus (GEO), Human Protein Atlas (HPA), and Clinical Proteomic Tumor Analysis Consortium (CPTAC), to assess the expression patterns, prognostic implications, DNA methylation, genomic alterations, and associated tumor immune microenvironments of FAM genes. Differentially expressed genes were pinpointed using the DESeq2 package. Least absolute shrinkage and selection operator (LASSO) Cox regression and a nomogram model were employed to identify prognostic FAM genes and estimate the survival outcomes for HCC patients. We performed tissue microarrays and immunohistochemistry on samples from 48 HCC patients to evaluate <i>FAM50A</i> expression. <i>FAM50A</i> was also knocked down in HCC cell lines to investigate its biological functions.</p><p><strong>Results: </strong>Five overexpressed and signature-related FAM genes (<i>FAM50A</i>, <i>FAM83D</i>, <i>FAM104B</i>, <i>FAM220A</i>, and <i>FAM222B</i>) were identified and validated at both mRNA and protein levels. Elevated FAM50A expression was linked to advanced tumor stage, higher grade, and unfavorable prognosis. The constructed prognostic nomogram accurately predicted 1- and 3-year survival outcomes based on tumor stage, status, and <i>FAM50A</i> expression levels. Pathways enriched in <i>FAM50A</i> co-expressed genes included RNA processing, oxidative phosphorylation, and cell cycle regulation. Additionally, <i>FAM50A</i> expression was associated with immune cell infiltration and immune checkpoint activity. Knockdown of <i>FAM50A</i> led to the suppression of HCC cell proliferation, migration, and invasion.</p><p><strong>Conclusions: </strong>This study identifies five FAM genes with prognostic relevance in HCC, among which FAM50A emerges as a potential independent prognostic biomarker and therapeutic target.</p>\",\"PeriodicalId\":23216,\"journal\":{\"name\":\"Translational cancer research\",\"volume\":\"14 8\",\"pages\":\"4720-4747\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432667/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tcr-2025-171\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-2025-171","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/25 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Exploration of signature-related FAM genes and correlation between FAM50A expression and the pathogenesis and prognosis of hepatocellular carcinoma.
Background: Hepatocellular carcinoma (HCC) ranks among the deadliest malignancies worldwide, with limited therapeutic options and poor prognosis for advanced-stage patients. The family with sequence similarity (FAM) genes are expected to be potential regulators in tumorigenesis, but their roles in HCC remain poorly understood. This study aimed to systematically investigate the expression profiles and functional roles of FAM genes in HCC.
Methods: We leveraged multiple databases, including The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), International Cancer Genome Consortium (ICGC), Gene Expression Omnibus (GEO), Human Protein Atlas (HPA), and Clinical Proteomic Tumor Analysis Consortium (CPTAC), to assess the expression patterns, prognostic implications, DNA methylation, genomic alterations, and associated tumor immune microenvironments of FAM genes. Differentially expressed genes were pinpointed using the DESeq2 package. Least absolute shrinkage and selection operator (LASSO) Cox regression and a nomogram model were employed to identify prognostic FAM genes and estimate the survival outcomes for HCC patients. We performed tissue microarrays and immunohistochemistry on samples from 48 HCC patients to evaluate FAM50A expression. FAM50A was also knocked down in HCC cell lines to investigate its biological functions.
Results: Five overexpressed and signature-related FAM genes (FAM50A, FAM83D, FAM104B, FAM220A, and FAM222B) were identified and validated at both mRNA and protein levels. Elevated FAM50A expression was linked to advanced tumor stage, higher grade, and unfavorable prognosis. The constructed prognostic nomogram accurately predicted 1- and 3-year survival outcomes based on tumor stage, status, and FAM50A expression levels. Pathways enriched in FAM50A co-expressed genes included RNA processing, oxidative phosphorylation, and cell cycle regulation. Additionally, FAM50A expression was associated with immune cell infiltration and immune checkpoint activity. Knockdown of FAM50A led to the suppression of HCC cell proliferation, migration, and invasion.
Conclusions: This study identifies five FAM genes with prognostic relevance in HCC, among which FAM50A emerges as a potential independent prognostic biomarker and therapeutic target.
期刊介绍:
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.